The TAB2 (TGF-beta activated kinase 1/MAP3K7 binding protein 2) antibody is a tool used to study the TAB2 protein, a key adaptor molecule in intracellular signaling pathways. TAB2 facilitates signal transduction by linking upstream regulators like TRAF6 to downstream kinases such as TAK1 (MAP3K7), particularly in the NF-κB and MAPK pathways. These pathways are central to innate immunity, inflammation, and stress responses, making TAB2 critical in processes like cytokine production, cell survival, and apoptosis.
TAB2 dysfunction has been implicated in diseases including cancers, autoimmune disorders, and cardiovascular conditions. For example, chromosomal deletions or mutations in TAB2 are associated with congenital heart defects and Noonan syndrome-like syndromes. Its role in modulating inflammatory signals also links it to conditions like rheumatoid arthritis and metabolic disorders.
Antibodies targeting TAB2 enable researchers to detect protein expression, localization, and interaction partners via techniques like Western blotting, immunoprecipitation, and immunofluorescence. Specific TAB2 antibodies help investigate post-translational modifications (e.g., ubiquitination) or subcellular trafficking under stimuli such as TNF-α, IL-1β, or pathogen-associated molecules. Commercial TAB2 antibodies are typically validated for cross-reactivity, epitope specificity (e.g., C-terminal or N-terminal regions), and compatibility with human, mouse, or rat samples. These reagents are essential for dissecting TAB2's context-dependent roles in health and disease.